APA (7th ed.) Citation

Bullock, T. A., Galpayage Dona, K. N. U., Hale, J. F., Morales, P., Jagerovic, N., Andrews, A. M., & Ramirez, S. H. (2023). Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair. NeuroImmune Pharmacology & Therapeutics, 2(4), 387. https://doi.org/10.1515/nipt-2023-0016

Chicago Style (17th ed.) Citation

Bullock, Trent A., Kalpani N. Udeni Galpayage Dona, Jonathan F. Hale, Paula Morales, Nadine Jagerovic, Allison M. Andrews, and Servio H. Ramirez. "Activation of CB2R by Synthetic CB2R Agonist, PM289, Improves Brain Endothelial Barrier Properties, Decreases Inflammatory Response and Enhances Endothelial Repair." NeuroImmune Pharmacology & Therapeutics 2, no. 4 (2023): 387. https://doi.org/10.1515/nipt-2023-0016.

MLA (9th ed.) Citation

Bullock, Trent A., et al. "Activation of CB2R by Synthetic CB2R Agonist, PM289, Improves Brain Endothelial Barrier Properties, Decreases Inflammatory Response and Enhances Endothelial Repair." NeuroImmune Pharmacology & Therapeutics, vol. 2, no. 4, 2023, p. 387, https://doi.org/10.1515/nipt-2023-0016.